No Data
No Data
Jaguar Health Unit Secures New European, Australian Patents; Shares Rise
Jaguar Health (JAGX) unit Napo Pharmaceuticals said Monday it secured new patents from the European and Australian patent offices for its plant-based prescription drug crofelemer.The European patent c
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
New patents issued for core rare disease target indications for crofelemerNapo has approximately 200 patents issued and pendingJaguar is supporting investigator-initiated proof-of-concept studies of c
Express News | Jaguar Health Regains Compliance With Nasdaq
Express News | Jaguar Health Inc - to Report Pivotal Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on or Before July 23
Express News | Jaguar Health Inc - Regains Compliance With Nasdaq S Bid Price Requirement
Jaguar Health Regains Compliance With Nasdaq's Bid Price Requirement
JAGX's securities continue to be listed and traded on NasdaqJaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024SAN FRANCIS
No Data